Response rate in all intent-to-treat patients and by cytogenetic abnormalities
| Response category, n (%) . | All evaluable patients, N = 32 . | Hyperdiploid, n = 10 . | Del(13), n = 9 . | Del(17p), n = 5 . |
|---|---|---|---|---|
| ORR | 16 (50) | 5 (50) | 1(11) | 4 (80) |
| VGPR | 5 (16) | 1 (10) | 1(11) | 1 (20) |
| PR | 11 (34) | 4 (40) | 0 | 3 (60) |
| MR | 5 (16) | 3 (30) | 3 (33) | 0 |
| SD | 8 (25) | 2 (20) | 5 (56) | 1 (20) |
| PD | 3 (9) | 0 | 0 | 0 |
| Response category, n (%) . | All evaluable patients, N = 32 . | Hyperdiploid, n = 10 . | Del(13), n = 9 . | Del(17p), n = 5 . |
|---|---|---|---|---|
| ORR | 16 (50) | 5 (50) | 1(11) | 4 (80) |
| VGPR | 5 (16) | 1 (10) | 1(11) | 1 (20) |
| PR | 11 (34) | 4 (40) | 0 | 3 (60) |
| MR | 5 (16) | 3 (30) | 3 (33) | 0 |
| SD | 8 (25) | 2 (20) | 5 (56) | 1 (20) |
| PD | 3 (9) | 0 | 0 | 0 |
PD, progressive disease; SD, stable disease.